Lupin shares gain 3% after USFDA approval for $1
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease, Lupin said.
Source
<meta name="google-adsense-account" content="ca-pub-6363428395369086">
- Petrol, Diesel Fresh Prices Announced: Check Rates In Your City
- Oil prices may fall further on China slowdown, IEA chief